Objective: To investigate the clinical and magnetic resonance imaging (MRI) features of anti-myelin oligodendrocyte glycoprotein (MOG) antibody-seropositive pediatric demyelinating syndromes. Methods: Serum samples collected from 74 children with suspected demyelinating disorders whom were being followed at Massachusetts General Hospital were incubated with control green fluorescent protein (GFP)-and MOG-GFP-transfected Jurkat cell clones. The binding ratios were calculated using flow cytometry. Using statistical analyses, we compared the demographic, clinical and radiological features in our seropositive and seronegative patients.
Introduction
There is increasing evidence of B-cell autoimmune mechanisms in the pathogenesis of inflammatory demyelinating diseases (DD). 1, 2 We and others have previously reported anti-myelin oligodendrocyte glycoprotein (MOG) antibodies (Abs) in pediatric DD cases, predominantly in children with an acute disseminated encephalomyelitis (ADEM)-like first episode 3, 4 and in children with multiple sclerosis (MS) with onset at < 10 years of age. 5 More recently, high titers of MOG-IgG Abs were observed in several pediatric cases with recurrent optic neuritis (ON), 6 seronegative neuromyelitis optica (NMO), 7, 8 and in a group of young patients with ADEM-like onset followed by monophasic or recurrent ON (ADEM-ON). 8 MOG seropositivity is also reported in a subset of adults with seronegative NMO and high-risk NMO (recurrent ON / recurrent longitudinally extensive transverse myelitis (LETM)). [9] [10] [11] [12] Given the broadening array of clinical phenotypes described to be associated with MOG Abs, particularly in the pediatric population, we asked whether there is a common clinical and radiological phenotype and clinical outcome associated with the seropositivity for MOG Abs in children with DD. In addition, we assessed the longitudinal outcomes of seropositive children.
To address these questions, we measured anti-MOG Abs, using our previously-described cell-based assay, 5 in serum samples from 74 children with acquired central nervous system (CNS) inflammation whom were followed at our clinic. We compared the clinico-radiological phenotype and disease course in groups of MOG antibody seropositive versus seronegative patients.
Methods

Patients
We enrolled 74 patients, with acquired demyelination of the CNS and onset prior to age 18 whom were diagnosed between 2004 and 2012, in a biomarker study at the Partners Pediatric MS Center at Massachusetts General Hospital, MA, USA. All eligible patients diagnosed with an acquired DD at the clinic within this time frame were enrolled in the biomarkers study and contributed to this analysis. We used the first available blood samples from each of all patients, for this study. The patients had the following diagnoses by the last visit: seven with ADEM, 12 with clinicallyisolated syndrome (CIS) (ON, TM), 45 with MS, four with NMO, two with radiologically-isolated syndrome (RIS). Four with non-specific DD, which did not meet the aforementioned criteria.
Pediatric MS and ADEM were diagnosed using the International Pediatric MS Study Group (IPMSSG) criteria (polysymptomatic clinical presentation with evidence of encephalopathy). 13, 14 Patients with only one first clinical inflammatory event, such as ON or TM, and no evidence of encephalopathy were diagnosed as CIS, according to the IPMSSG criteria. Patients were diagnosed as NMO when presenting with ON, TM and at least two of these three criteria: magnetic resonance imaging (MRI) evidence of a contiguous spinal cord lesion (⩾ 3 segments in length), brain MRI nondiagnostic for MS and NMO IgG seropositivity, to be consistent with current diagnostic criteria. 14, 15 Children diagnosed with non-specific DD had demyelinating syndromes that did not meet the aforementioned criteria. We also collected serum samples from 23 pediatric healthy controls, under the same protocol.
Regarding the standard protocol approvals, registrations and patient consents, Institutional Review Board (IRB) approval was granted by the Partners Human Research Committee.
Sample collection and storage
Blood samples were collected in plastic heparincoated plasma/serum tubes and then the serum was extracted and stored at -80 o C, within 4 hours of the blood draw.
MOG antibody detection assay
Green fluorescent protein (GFP) controls and MOG-GFP were used to generate stably transfected Jurkat clones, as described in previous publications. 3, 5 These cells were stored in liquid nitrogen tanks, thawed and cultured in DMEM medium (Invitrogen) enriched with 10% fetal bovine serum (FBS, Fisher/Lonza), a penicillin-streptomycin mixture of 10 mg/ml (Fisher/ Lonza), 35 mM HEPES (Fisher/Lonza), 2 mM Glutamax (glutamine solution from Invitrogen), and 1mg Geneticin powder (Invitrogen) to maintain selection. The presence of GFP and MOG antigen in the cells was confirmed by Western blot (Millipore).
The cells were harvested, washed in phosphate buffered saline (PBS, Fisher/Lonza) with 1% bovine serum albumin (BSA, Sigma-Aldrich) and resuspended to 1 million cells per mL. We incubated 1 uL of the serum sample for 1 hour with 50,000 MOG-GFP and GFP-control cells per well of 96-well, U-bottom plates, at 4ºC. After washing twice with staining buffer, the cells were incubated in R-Phycoerythrin-conjugated F (ab') 2-fragment donkey anti-human IgG (Jackson) diluted to a 1:1000 ratio, in PBS/BSA (Fisher Lonza) and 10% BSA. The cells were washed again twice; and then incubated in a live/dead cell solution, reconstructed with 1 ul of violet fluorescent reactive dye (Invitrogen) in 1ml of distilled water (diH 2 O) and 9 ml of PBS, for 20 minutes at 4ºC. We used mouse monoclonal anti-MOG IgG Abs, clone 8-18C5 (Millipore), as the primary Ab for our positive controls. We used 1% paraformaldehyde for fixation during 10 minutes. The cells were then resuspended in PBS/BSA until acquisition in the BD LSR-II flow cytometer (Becton Dickinson). The results were analyzed with Tree Star Flowjo 8.8.6. software.
To classify patients as MOG Ab positive or negative, samples from the pediatric healthy controls were run along with the patient samples, on each plate. The MOG binding ratios were corrected for background, by subtracting the plate-specific mean binding ratios for the healthy controls, to avoid differences between plates. Patients with corrected binding ratios > 5 (more than 3 SD from the controls) were considered positive for all analyses, as per our prior study. 5 
Clinical data
We prospectively collected the number, symptoms and location of each demyelinating attack; and this data was stored in our longitudinal pediatric DD electronic Oracle-based database, 16 with posterior validation by the authors. Symptoms were classified as visual, motor, sensory, cerebellar, bowel/bladder dysfunction and encephalopathy. Attack locations were classified as optic nerve, brainstem-cerebellar, cerebrum and spinal cord. Disability scores and attack severity were measured using the Expanded Disability Status Score (EDSS) scale.
MRI analysis
Analysis of brain and spinal MRIs was performed by a pediatric neurologist blinded to clinical diagnosis, who had undergone MRI lesion assessment training by the senior authors, and the lesion distribution was assessed by a qualitative protocol, presented in a previous work. 17, 18 We reviewed the T2 and FLAIR sequences from the MRIs available in our computerized system, performed within 6 months of serum sampling.
The brain lesion location was classified (using a representative number) as: cortical (1), subcortical (2), periventricular (3), corpus callosum (CC) (4), optic chiasm (5), thalamus (6), brainstem (7) , area postrema (8) and cerebellum (9) . The spinal lesions were categorized according to the level involved and the extension, both longitudinal and cross-sectional: whole spine (1), partial spine (2) and central grey matter (3). If a lesion was big enough to occupy two locations, it was counted twice (example, a periventricular lesion involving the CC was counted as being both periventricular and callosal).
Statistical analysis
All analyses compared the MOG-seropositive subjects to MOG-seronegative subjects. Continuous and ordinal variables were compared using a Wilcoxon rank sum test, and dichotomous/categorical variables were compared using Fisher's exact test. To compare the relapse rate after the blood draw in the two groups, we used a Poisson regression model with an overdispersion parameter. To compare the EDSS scores in the two groups, we used a Wilcoxon rank sum test. Finally, we used Silverman's test to assess if there was statistical evidence that age distribution in the MOG-positive subjects had more than one mode; and this test was fit using the Silverman test library in the statistical package R (www.rproject.org). 19, 20 
Results
Demographic features
The baseline demographic characteristics of the MOG-positive and -negative subjects are presented in Table 1 : There were 13 of the 74 subjects who were seropositive at the time of the blood draw. The MOGseropositive patients were significantly younger at the time of blood draw (Table 1 ) and younger at the disease onset, compared to the seronegative patients ( Table 2 ). The groups did not differ significantly in terms of gender, race or ethnicity. The two groups were also not significantly different, in terms of family history of MS nor other autoimmune diseases.
MOG antibody binding ratios by disease category are presented in Figure 1 .
The overall final disease category differed between the seropositive and seronegative patients (p = 0.021), as the seronegative subjects were significantly more likely to have MS or CIS than the seropositive subjects (p = 0.0078).
Age at onset and onset symptom features
The first symptom type and first symptom location for the seropositive and seronegative patients are presented in Table 2 . Seropositive subjects were significantly more likely to have encephalopathy as the first symptom (p = 0.012). No other group differences reached statistical significance.
Mean age at onset was significantly younger in the seropositive patients (9.9 ± 5.7 versus 13.7 ± 3.5; p = 0.046). The distribution of age at onset in the seropositive group was distinctly bimodal (Silverman's test for one mode: p = 0.03), with a subset of seven young patients having onset between ages 3.3-7.7, while six older patients had an onset between 13.8-17.9. This bimodal distribution suggested the potential for two distinct types of seropositive patients ( Figure 2 ). We asked whether the first symptoms differed between the younger and older MOG seropositive patients. Interestingly, none of the older seropositive patients presented with encephalopathy as the first symptom, while 71.4% of the younger seropositive patients had encephalopathy as the first symptom was (p = 0.02). In contrast, five out of six of the older seropositive children presented with ON, compared to three out of seven of the younger seropositive children. Of the younger seropositive children, three out of seven had a final diagnosis of MS, three out of seven had a final diagnosis of ADEM, and one had the DD NOS, meeting the criteria for ADEM-ON. Of the older seropositive patients, two out of six had a final diagnosis of CIS, one out of six had MS, one out of six had nonspecific DD and two out of six had a final diagnosis of NMO. Despite a trend towards higher MOG antibody binding ratios in the younger children, compared to the older ones, this was not statistically significant (p = 0.161) (see the Supplementary Figure 1 ).
Four patients from this cohort met the diagnostic criteria for NMO. 15 Serum NMO IgG was tested at least twice in all four NMO patients. Only two out of four of these NMO patients were found to be seropositive for aquaporin four (AQP4) IgG. These two patients were seronegative for MOG. In contrast, the two out of four NMO patients who were seronegative for AQP4 IgG, were seropositive for MOG antibodies. One of these NMO patients had a monophasic course, while the other had an aggressive course with multiple relapses that were refractory to standard treatment.
Disease course
We asked whether the seronegative patients are more likely to have a polyphasic course of disease characterized by more than one attack during the follow-up period (mean 4-5 years since onset, Table 1 ). We found no difference between the two groups: 79.7% of seronegative patients and 61.5% of seropositive patients had a polyphasic course of disease (p = 0. 277).
The relapse rate in the follow-up period after the blood draw was not significantly different between the seropositive and seronegative patients ( Table 2 ). The EDSS scores at the time of the blood draw and the EDSS scores 2 years after the blood draw did not differ significantly between the two groups ( Table 2) .
Laboratory features
Laboratory features were measured in subsets of patients, and the available results are summarized in Table 3 . The number of white blood cells (WBC) in the cerebrospinal fluid (CSF) was significantly higher in the MOG-seropositive patients (p = 0.0004). Intrathecal IgG production and presence of oligoclonal bands did not differ between both groups. Positive Epstein-Barr virus (EBV) serology did not correlate with the presence of MOG antibodies. 
MRI features
The MRI characteristics of the brain and spinal cord at the scan closest to the blood draw are summarized in Table 4 . The only statistically significant difference between the seropositive and seronegative patients was the presence of CC lesions. CC lesions were present in 52% of seronegative patients and 0% of the seropositive patients (p = 0.012). Interestingly, thoracic lesions were present in eight out of 46 of the seronegative patients, and absent in zero out of seven seropositive patients, with thoracic MRIs; however, the difference between the groups was no statistically significant, given the limited sample size. The proportion of LETM was one out of two (50%) among the seropositive patients, compared to one out of 22 (6.67%) in the seronegative patients, but this difference was not statistically significant, given the limited sample size (p = 0.16).
Discussion
Anti-MOG antibodies have been described as being associated with several pediatric demyelinating syndromes, including ADEM, 3, 21, 22 relapsing-remitting MS (RRMS), 5,23 recurrent ON, 6 NMO-like disease, 24 and ADEM-like onset followed by monophasic or recurrent ON. 8 The goal of this study was to investigate, in an unbiased fashion, the clinical and radiologic phenotype of MOG-seropositive versus -seronegative patients, measured at one time-point, in a relatively large cohort of children with demyelinating diseases; in order to assess the clinical significance of this antibody. To address this gap, we compared demographic features, clinical and radiologic characteristics, laboratory findings and outcomes between the MOG-seropositive and -seronegative patients, evaluated using our previously published MOG transfectant flow cytometrybased assay. 5 We found that the MOG-seropositive patients were younger than the MOG-seronegative patients; however, they did not differ in other demographic features. There was not one predominant disease category amongst the seropositive patients, nor was one group more likely to have a polyphasic course. There was a bimodal distribution of MOG-seropositive patients by the age at onset, with a distinct younger group having a high prevalence of encephalopathy, and an older group whom presented almost exclusively with ON. Analysis of laboratory features showed that there was a higher WBC count in the CSF of the MOGseropositive patients. Analysis of qualitative MRI features showed that CC lesions were absent in the seropositive patients, as well as thoracic cord lesions; however, the latter did not reach statistical significance. The relapse rate and EDSS score after 2 years did not differ between groups.
To our knowledge, no previous reports have addressed differences in clinical and radiological features between MOG-seropositive and -seronegative children with DD. When only cell-based assays were considered, the prevalence of MOG Abs is found to be higher in the pediatric than in the adult patients. [3] [4] [5] [6] 9, 12, 23, [25] [26] [27] We previously reported a higher prevalence of anti-MOG Abs among children younger than 10 at disease onset. 5 Our current work also showed a significantly younger mean age among seropositive patients, with no significant differences in other demographic features.
A recent paper by Baumann et al. 28 showed that of 19 ADEM children with or without MOG Abs, there was no difference in their age, sex ratio nor range of clinical symptoms; however, they found that the MOG antibody-positive children with ADEM had large, hazy and bilateral lesions, in the absence of welldefined, small lesions. Our detailed analysis showed two distinct age groups amongst the seropositive patients, whom differed in clinical presentation, with the younger patients being more likely to have encephalopathy (as is noted in prior studies), and the older patients presenting with ON. Indeed, the presence of encephalopathy was a distinguishing feature amongst our MOG-seropositive versus MOGseronegative patients, which might also be a function of their younger age. 29 The dichotomy by age group raises questions about the role of development and puberty in clinical presentation. 30 Because few experimental studies demonstrate the presence of severe ON and spinal cord demyelination in animal models over-expressing MOG, [31] [32] [33] [34] [35] several authors have correlated the presence of MOG Abs with ON and NMO. We did not find a statistically significant difference in the presence of ON as a first symptom located when taking into account all patients, but this was a presenting feature of our older seropositive patients.
In contrast to other studies, we did not find one final DD category associated with MOG antibodies in children. We had four NMO patients in this study. Interestingly, two out of the four NMO patients that were MOG Ab-positive were negative for AQP4 Abs, while the other two out of four NMO patients whom were seronegative for MOG Abs, were AQP4 positive. MOG-seropositive adults 9-12 and children 28 with NMO have been described to have a more benign course and more frequent ON. In contrast, although ON was the predominant presenting symptom in our older MOG-seropositive group, one of our two MOGseropositive NMO patients had an aggressive disease course with frequent relapses. ADEM-ON is a DD phenotype that more often presents in children than in adults, and has been previously associated with MOG antibodies. 8 One of our seropositive patients met the criteria for ADEM-ON; however, we also had two patients with this phenotype whom were MOG seronegative.
MOG-seropositive adults reportedly have more frequently had spinal cord lesions that are distributed in Figure 2 . Age at first symptom, for MOG-seropositive and -seronegative patients. Figure 2 shows the two distinct age groups amongst MOG-seropositive pediatric patients: a younger group between the ages of 4-8 and an older group between the ages of 10-13. The distribution of age at onset in the seropositive group was distinctly bimodal (Silverman's test for one mode: p = 0.03), with a subset of seven young patients having onset between ages 3.3-7.7, while six older patients had an onset between the ages of 13.8-17.9. None of the older seropositive patients presented with encephalopathy as the first symptom, while five out of seven (71.4%) of the younger seropositive patients had encephalopathy as their first symptom (p = 0.02). In contrast, five out of six of the older seropositive children presented with ON, compared to three out of seven of the younger seropositive children.
the thoracic and lumbar spinal cord. 10 This contrasts to our pediatric MOG-seropositive patients, whom showed a striking absence of thoracic cord lesions;
however, this finding did not reach statistical significance, given the small sample size, and should therefore be interpreted with caution. 28 also suggest the absence of atypical features (such as CC lesions) in MOG-seropositive children with ADEM, compared to seronegative children. Whether this represents a characteristic radiologic feature of the seropositive patients should be addressed in future studies with larger numbers of DD and NMO patients, as this may be helpful to distinguish the MOG-seropositive TM/NMO from classic NMO. These differential patterns of MRI regional involvement may reflect developmental differences in MOG expression, which generally proceed caudal to rostral. 36 Given that MOG-seropositive patients are more likely to be younger, the absence of CC lesions may reflect a relatively lower expression of MOG in that region, although there is limited data on the temporality of regional MOG expression in humans. Moreover, the observed bimodal distribution of the MOG-seropositive cases, with the younger patients presenting with ADEM, while the older patients presented with ON, may reflect the relative levels of regional expression of the MOG antigen in the different age groups. This hypothesis requires further validation, through longitudinal studies of MOG expression in humans.
As was previously reported, 28 our MOG-seropositive patients had significantly higher number of WBC in their CSF, suggesting more of an inflammatory burden in the acute phase, as compared to the seronegative patients. This may also be a reflection of the younger age at onset, as higher WBC counts have been described in pre-pubertal children with MS. 37 We did not find a correlation between EBV and MOG serostatus, in agreement with previous literature. 26 In contrast to studies in MOG-seropositive NMO pediatric 7,28 and adult patients, 12 as well as pediatric ON, 6 we did not find any difference in the relapse frequency and disability scores after 2 years, in our seropositive and seronegative cohorts. This may be because of the diverse phenotypes and disease categories of the children studied in our cohort. Further larger studies may explore the outcomes, using larger clinical subgroups of pediatric patients.
In a longitudinal study, Di Pauli et al. 4 find that MOG IgG dynamics correlate well to ADEM disease course (IgG declined and disappeared with full ADEM recovery), but not the CIS cases. MOG IgG titers in the MS group showed rather stable low positive levels, without significant difference between the RRMS and primary progressive MS (PPMS) patients. Probstel et al. 23 found similar results in a prospective study of 77 pediatric patients with acute demyelinating events. More recently, Baumann et al. 28 compared a group of MOG-seropositive versus MOGseronegative children with ADEM, finding that the MOG titers decline with time, in the seropositive group. 28 We did not have sufficient longitudinal samples to assess their findings in this cohort.
Our study had several limitations, including the relatively small number of patients, especially NMO patients, and the limited follow-up period. Approximately 25% of our patients had received steroids or disease modifying treatment (DMT) in the 30 days prior to sample acquisition; however, those treatments had not previously been shown to be determinants of MOG antibody status. In addition, we did not have longitudinal samples in the majority of our patients, to assess longitudinal dynamics. Different MOG-Ab detection methods have led to different results, even using cell-based assays. 38 This limitation should be taken in account when comparing assays that use full-length MOG protein, versus the extracellular truncated domain that was used here.
In summary, we found serum MOG antibodies in a broad spectrum of children with DD diagnoses. Common underlying features were a younger age; presentation with encephalopathy, particularly in the younger patients; and ON in the older patients, suggesting that the presence of antibodies was associated with a constellation of presenting symptoms. The NMO patients who were seropositive for MOG were seronegative for AQP4; and one had an aggressive disease course, which contrasts with MOGseropositive adults with NMO. There were no significant differences in the longitudinal outcomes, including polyphasic course, the annualized relapse rate (ARR) and EDSS after 2 years, suggesting that cross-sectional evaluation of MOG antibodies has limited prognostic potential. This study contributed to the growing literature; and in future studies, we aim to assess longitudinal dynamics, as well as IgG subtype. Further studies in larger, longitudinal cohorts stratified by specific clinical and radiological presentations are needed to consolidate the long-term prognostic value of MOG antibodies in children with DDs.
